General Partner at Hatteras Venture Partners
Clay B. Thorp is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena and co-founded Hatteras Venture Partners in 2000. Since co-founding Hatteras, Mr. Thorp has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. He has led investments in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics, and research informatics.
Mr. Thorp began his career in 1995 when he co-founded Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA, and proteins. Shortly thereafter, he co-founded Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000.
Mr. Thorp has led investments and numerous strategic transaction processes in a variety of portfolio companies, including G1 Therapeutics, Clearside Biomedical, Lysosomal Therapeutics, Asthmatx, PhaseBio Pharmaceuticals, ArtusLabs, Embrella, and Synthematix.
Mr. Thorp currently serves as Executive Chairman of PhaseBio Pharmaceuticals and Chairman of GeneCentric Diagnostics. He is also on the boards of Clearside Biomedical (NASDAQ: CLSD), Rodin Therapeutics, Lysosomal Therapeutics, StrideBio, and Orig3n. He serves on the Chancellor’s Philanthropic Committee and the Board of Visitors of the Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, and on the board of the NC School of Science and Mathematics Foundation.
Mr. Thorp holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill.